Cancer cells typically shift their metabolism to aerobic glycolysis to fulfill the demand of energy and macromolecules to support their proliferation. Glucose transporter (GLUT) family-mediated glucose transport is the pacesetter of aerobic glycolysis and, thus, is critical for tumor cell metabolism. Yin Yang 1 (YY1) is an oncogene crucial for tumorigenesis; however, its role in tumor cell glucose metabolism remains unclear. Here, we revealed that YY1 activates GLUT3 transcription by directly binding to its promoter and, concomitantly, enhances tumor cell aerobic glycolysis. This --
for building macromolecules, including ribonucleic acids, proteins and lipids, 2, 3 but also nicotinamide adenine dinucleotide phosphate, which is critical for tumor cell antioxidant defense. 4 Glucose transport across the cell membrane is the pacesetter for glucose metabolism in cells 5 and is mediated by the facilitative SLC2 family of glucose transporters (GLUT). 6 Currently, 14 members of the GLUT family have been identified, each of which likely have specific spatial and temporal distributions, as well as distinct substrate selectivity and transport kinetics. [6] [7] [8] Consistent with the excessively high glucose consumption of tumor cells, 1 aberrant GLUT family expression has been found in various cancers, including colorectal cancer, 9 brain cancer, 10 and lung cancer cells. 11 Despite the fact that the GLUT family is critical in tumor cell metabolic reprogramming, the detailed regulatory mechanism has not been fully elucidated.
Yin Yang 1 (YY1) is a GLI-Krüppel class protein with 4 C2H2 zinc finger domains that is evolutionarily well conserved throughout all vertebrate lineages. [12] [13] [14] YY1 can activate or inhibit transcriptional activation of its target genes depending on its binding context. 15, 16 Accordingly, YY1 has been reported to play crucial roles in various physiological functions, including gestation, embryonic development, cell differentiation and cell cycle. [17] [18] [19] [20] YY1 is upregulated in various human cancers, including colon carcinoma, breast carcinoma and prostate cancer. [21] [22] [23] We and other groups have reported that YY1 is an oncogene that can promote tumorigenesis by enhancing cell proliferation, tumor angiogenesis and tumor metastasis, 15, 19, 24 and that these regulatory effects occur in both a p53-dependent and p53-independent manner. 20, 24 However, despite its critical roles in tumorigenesis, it remains unclear whether YY1 is involved in tumor cells' glucose metabolism.
In this study, we revealed for the first time that YY1 enhances the transcription of GLUT3, the member of the GLUT family with high affinity for glucose, and, in turn, promotes glucose consumption and lactate production in colorectal tumor cells. Furthermore, we found that this regulation of transcriptional activity occurs most plausibly through a direct binding of YY1 to the GLUT3 promoter.
This metabolic alteration toward glycolysis subsequently supported YY1-induced tumorigenesis. Importantly, we found that the regulatory effect of YY1 on the GLUT3 promoter, and, concomitantly, the function of YY1/GLUT3 axis in altering tumor cell metabolism and promoting tumorigenesis, occurs in a p53-independent manner.
Together, these results reveal an essential function of YY1 that links it to the entry of the tumor cell glucose metabolism and provide a new perspective on the multiple functions of YY1 in tumorigenesis.
Furthermore, these findings emphasize the potential of targeting YY1 for cancer therapy, irrespective of the p53 status. 
| MATERIALS AND METHODS

| Cell lines and cell culture
| Animal experiments
For the xenograft experiment, BALB/c-nu/nu mice (male; body weight, 18-22 g; 6 weeks old) were purchased from the Third Mili- /shYY1/ GLUT3 cells. Tumor size (V) was evaluated as described previously. 24 The investigator was blinded to the group allocation and during the assessment.
| Quantitative RT-PCR and western blotting
Detailed methods for quantitative RT-PCR and western blotting are described in Supplementary Data S1. The primers and antibodies used are listed in Supplementary Tables S1 and S2, respectively.
| Statistical analysis
All values of the experimental results are presented as mean ± SD of triplicates. Statistical analysis was performed using Student's t test.
For clinical samples and xenograft experiments, statistical analysis was performed using one-way ANOVA. A value of *P < .05 was considered statistically significant.
| RESULTS
| Yin Yang 1 regulates GLUT3 expression in tumor cells
Glucose metabolism is critical for the highly proliferative tumor cells, and the GLUT family is the pacesetter of glucose intake. To investigate whether YY1 affects the expression of members of the GLUT family, we examined the effect of an shRNA vector targeting YY1
(shYY1-1) on the expression of GLUT family members in human colon carcinoma HCT116 WT cells. As shown in Figure 1A , YY1 significantly affected GLUT1 and GLUT3 expressions, while it only slightly affected GLUT6 expression and did not affect GLUT8 expression. In contrast, GLUT2, GLUT4, GLUT5 and GLUT7 could not be detected in colon carcinoma cells.
Among the GLUT family affected by YY1 silencing, GLUT3 has the highest affinity to glucose. 8, 11 To further confirm the regulatory effect of YY1 on GLUT3, we transfected 2 shRNAs targeting YY1 at different sites, as well as YY1 overexpression vector (Supplementary Figure S1 ), and investigated their effects on GLUT3 expression. As shown in Figure 1B , YY1 silencing robustly reduced GLUT3 mRNA expression (left) in colon carcinoma cells, while YY1 overexpression clearly induced it (right). A similar tendency was observed for protein expression ( Figure 1C ). Thus, our results showed that YY1 might regulate GLUT3 at the transcriptional level.
| Glucose transporter 3 is involved in Yin Yang
1-induced tumor cell metabolic shift and proliferation
Given that GLUT3 is critical for glucose transport into the cells, we were examined using western blotting. β-actin was used for qPCR normalization and western blotting loading control. Cells transfected with shCon or pcCon were used as control. Quantitative data are shown as relative to control and expressed as mean ± SEM from 3 independent experiments. *P < .05; **P < .01; ND, not detected; NS, not significant; pcCon, pcDNA3.1(+)
Next, we investigated whether GLUT3 is involved in the YY1-mediated regulation of the metabolic shift. We cotransfected both shYY1 and GLUT3 overexpression vectors (pcGLUT3, Supplementary 
| Yin Yang 1 enhances tumor cell glycolysis in a p53-independent manner
A previous study reported that YY1 negatively regulates p53, 20 while p53 suppresses GLUT3 expression. 28 However, we previously revealed that YY1 regulates tumor cell proliferation even in the absence of p53. 24 These facts led us to question whether YY1 could enhance GLUT3 expression and induce tumor cell metabolic shift in a p53-independent pathway. To this end, we examined the effect of YY1 silencing on GLUT3 expression and found that despite the absence of p53, YY1 silencing could still suppress GLUT3 mRNA expression in HCT116 p53null cells ( Figure 3A , left), while YY1 overexpression significantly induced it ( Figure 3A, right) . A similar tendency was observed in GLUT3 protein expression: YY1 positively regulates GLUT3 protein expression in HCT116 p53null cells ( Figure 3B ). Indeed, we found that despite the absence of p53, YY1 positively regulates glucose consumption ( Figure 3C) . Similarly, the lactate production in the HCT116 p53null cells showed a positive correlation with the YY1 expression level ( Figure 3D ). These results clearly indicated that YY1
induces the tumor cell glucose metabolic shift by regulating GLUT3
in a p53-independent manner.
To investigate whether p53-independent YY1 regulation of tumor cell metabolism, and subsequently tumor cell growth, occurs via its regulatory effect on GLUT3, we overexpressed GLUT3 in YY1-silenced HCT116 p53null cells. We found that both the glucose consumption and the lactate production, which was repressed by YY1 silencing, were conspicuously restored by GLUT3 overexpression ( Figure 3E,F) . Given that tumor cells prefer to use aerobic glycolysis for producing ATP, we investigated the role of the YY1/GLUT3 axis in intracellular ATP production and found that in p53-null cells, YY1 silencing robustly suppressed intracellular ATP level, while GLUT3 overexpression significantly restored it ( Figure 3G ).
Next, we examined whether p53-independent YY1 regulation of GLUT3 affects tumor cell proliferation and colony formation poten- Oxaliplatin, which is commonly used for treating colon carcinoma, had been reported to affect tumor cell glucose metabolism. 29, 30 We next examined the effect of oxaliplatin on YY1 and GLUT3 expression. As shown in Figure 4D , oxaliplatin grossly suppressed the expression levels of both YY1 and GLUT3 in Figure 4E,F) . These results suggested that oxaliplatin suppresses tumor cell proliferation by, at least partly, inhibiting the YY1/GLUT3 pathway-mediated glucose metabolism.
| Yin Yang 1 directly affects glucose transporter 3 transcriptional activity
Next, we questioned whether YY1 could directly regulate GLUT3 transcription. To this end, we first examined the effect of YY1 on a firefly reporter vector bearing the −1004 to +258 region of the GLUT3 promoter (GLUT3-Luc, Supplementary Figure S4A) . The activity of GLUT3-Luc was suppressed in both YY1-silenced HCT116 WT and HCT116 p53null cells ( Figure 5A ). Concomitantly, GLUT3-Luc activity was enhanced in both cells when YY1 was overexpressed ( Figure 5B ), indicating that YY1 positively regulates GLUT3 promoter activity, irrespective of p53 status. Using the UCSC Genome Browser, 31 we found a predicted putative YY1 binding site (GACATTTT) 32 at the +158 to +165 region of the GLUT3 promoter. Through ChIP assay, we demonstrated that YY1 could directly bind to the +81 to +251 region of the GLUT3 promoter ( Figure 5C ). We then constructed another GLUT3
reporter vector bearing the −1004 to +170 region of the GLUT3 promoter (GLUT3(s)-Luc), and a GLUT3 reporter vector without the pre- To confirm the importance of the predicted binding site, we further constructed a mutated GLUT3 reporter vector (GLUT3(mut)-Luc) by inducing 3 mutations into the putative YY1 binding sequence (Supplementary Figure S4B) . As shown in Figure 5F ,G, YY1 silencing and overexpression failed to affect the luciferase activity of mutant GLUT3 reporter vector in both wild-type and p53-null cells, indicating that binding to GLUT3 promoter is essential for YY1 regulation on GLUT3 promoter activity.
Mutation of threonine to arginine at 372 positions of YY1 had been shown to inhibit DNA binding of YY1. 33 Thus, we further examined GLUT3 transcriptional activity in HCT116 p53null cells overex- Together, these results clearly indicated that YY1 directly regulates GLUT3 transcriptional activity, and subsequently, glucose metabolism, by binding to GLUT3 promoter, and acts as a transcription factor.
| The p53-independent Yin Yang 1/glucose transporter 3 pathway is critical for tumor cell growth
To examine the function of the p53-independent YY1/GLUT3 pathway in tumorigenesis in vivo, we performed a xenograft experiment.
WANG ET AL. Cells transfected with shCon or pcCon were used as control. β-actin was used for qPCR normalization. Quantitative data were expressed as mean ± SEM from 3 independent experiments. **P < .01. NS, not significant; pcCon, pcDNA3.1(+) Figure S6 ) and analyzed their tumorigenic potential upon subcutaneous transplantation into BALB/c-nu/nu mice. We found that GLUT3 overexpression significantly restored the tumorigenic potential of HCT116 p53null cells suppressed by YY1 silencing (Figure 6A,B) .
Immunohistochemistry of tissue sections from the xenografted tumors confirmed the protein expression levels of YY1 and GLUT3 in the xenografted tumors: GLUT3 was downregulated in the tumor generated from HCT116 p53null /shYY1 cells ( Figure 6C ). Furthermore, Ki67 staining results also showed that the number of proliferative cells was conspicuously lower in tumors generated from YY1- /shYY1/GLUT3 stable cell lines were examined in vivo by subcutaneous injection into Balb/c-nu/nu mice (n = 5). Volumes of the tumors generated were measured at indicated time points (A), and the representative images are shown (B). C, Immunohistochemistry staining images against YY1 and GLUT3 in the tissue sections of xenografted tumors in Balb/cnu/nu mice injected with indicated cell lines (scale bars: 50 μm). D, Ki67 staining of the xenografted tumor in Balb/c-nu/nu mice injected with indicated cell lines. Low (scale bars: 100 μm) and high (scale bars: 50 μm) magnification images are shown. E, The mRNA expression levels of YY1 and GLUT3 in human clinical colon carcinoma and the corresponding adjacent tissue were determined using qPCR. F, G, The protein expression levels of YY1 and GLUT3 in human clinical colon carcinoma and the corresponding adjacent tissue were determined using western blotting (F) and immunohistochemistry staining against YY1 and GLUT3 (G, scale bars: 100 μm for low magnification, and 20 μm for high magnification). β-actin was used for qPCR normalization and western blotting loading control. **P < .01 silenced cells, while GLUT3 overexpression significantly restored it ( Figure 6D ). Figure S7) . Our results clearly showed that YY1 is a critical positive regulator of GLUT3. GLUT3 was initially identified in fetal skeletal muscle 36 and was later found to be predominantly expressed in neurons and brains. 8, 35 While its expression, normally, is strongly tissue-specific, high GLUT3 expression has been observed in various tumors, including colorectal carcinomas and brain tumors. 9, 10 Furthermore, GLUT3
| DISCUSSION
is involved in anti-angiogenic therapy resistance as well as in driving cancer stem cell phenotype. 36, 37 The critical roles of GLUT3 are most plausibly due to its high activity as a glucose transporter, with higher affinity for glucose than other Class I GLUT family members, including the widely expressed GLUT1. 7, 8 Indeed, GLUT3 has been reported as a potential target for anticancer therapy. 38 Our novel findings show that GLUT3 is positively regulated by YY1, which is highly expressed in various tumors, and, thus, elucidate a novel pathway for GLUT3 upregulation in tumor cells. Furthermore, these results indicate that a GLUT3-targeting therapeutic strategy could be achieved by targeting YY1.
Kawauchi et al 28 report that GLUT3 expression is regulated by tumor suppressor p53 through the IKK-NF-κB pathway, while Sui et al and Gronroos et al 20, 39 report that YY1 can suppress the transcription and stabilization of p53. Intriguingly, our results clearly showed that YY1 regulation of the transcriptional activity of GLUT3
and tumor cell aerobic glycolysis occurs even when p53 is lacking, and that this p53-independent regulation is critical for YY1-induced tumorigenesis in p53-null tumor cells. Activation of endogenous p53
has become a major strategy in treating cancers; 40 however, p53 mutation and aberrant expression are commonly found in cancers. 41 Thus, these results strongly suggest that YY1 silencing is a potential therapeutic strategy for treating tumors, irrespective of their p53
status.
Herein, we also showed that oxaliplatin, a drug commonly used for colon carcinoma, suppresses p53-null tumor cell proliferation by regulating the YY1/GLUT3 axis, suggesting that YY1 might be crucial for the antiproliferative effect of oxaliplatin. Although the detailed mechanism regarding how oxaliplatin suppresses YY1 F I G U R E 7 Schematic diagram showing the mechanism of Yin Yang 1 regulation on the tumorigenesis via direct transcriptional regulation on glucose transporter 3 expression needs to be further elucidated, these novel findings provide new insight into the pharmacology of oxaliplatin, as well as evidence for the potential of targeting YY1/GLUT3 axis as a therapeutic strategy.
In conclusion, we unraveled a novel role of YY1 in tumorigenesis by linking its oncogenic characteristic with glucose entry into the cells, the pacesetter of tumor cell aerobic glycolysis. These findings further suggest that YY1 is a crucial factor in tumorigenesis, and that it is a good potential target for treating cancers, irrespective of the p53 status. 
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